The AI-enabled clinical assistant is available to query patient data across the EHR as well as build custom agents to maximize workflow
CHICAGO, June 01, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the expansion of Tempus One—its generative AI clinical assistant—with direct integration into electronic health record (EHR) systems. By integrating AI at every point of the clinical care process, the expanded capabilities of Tempus One offer physicians in oncology and beyond more support in treatment decisions. Tempus One is uniquely positioned to offer these new features given the company’s depth and scale of EHR integrations with providers across the U.S.
Tempus has developed an integrated architecture that captures real-time clinical, molecular and imaging data from millions of patients and makes that data easily digestible and useful for clinicians and care teams. Through Tempus One, physicians can gain AI-enabled insights that transform how they interact with patient data, streamlining complex treatment decisions and reducing time spent on administrative tasks.
New capabilities in the latest iteration of Tempus One:
Integration of ASCO Guidelines: Tempus One is integrating ASCO’s clinical practice guidelines into the platform to equip physicians with the latest guidelines and information to guide personalized patient care. Oncologists are now able to easily access ASCO’s guidelines, which provide evidence-based, treatment and care recommendations.
Clinical Workflow Assistance: Tempus One has a suite of new features, designed to help physicians at every step with tailored insights and reduce the burden of administrative tasks.
Pre-Appointment Preparation: Tempus One summarizes patient history, treatment journey, and recent biomarker status, ensuring physicians are well-prepared for appointments.
Real-Time Support During Appointments: Tempus One can transcribe conversations, take intelligent notes, and highlight key information, allowing physicians to focus on patient care.
Post-Appointment Assistance: Tempus One supports documentation tasks, treatment planning based on updated guidelines and research, prepares prior authorizations, and facilitates clinical trial matching.
Agent Builder: Over the past several months, Tempus has used its Agent Builder GenAI tool internally to develop and deploy more than 1,000 AI agents. Now, Tempus is extending access to this toolset to a select group of partner providers, collaborating with them to create and test custom GenAI solutions tailored to their unique needs and preferences. The agents are designed to create efficiencies and streamline workflows, such as generating custom patient overviews to accelerate pre-charting or generating notes from conversations with patients to be added into their EHR records. These custom agents can be developed in collaboration with dedicated Tempus team members. By referencing institutions’ standard operating procedures and data repositories, these agents can be seamlessly integrated into existing workflows through One.
"As healthcare faces rising costs and growing complexity, no group bears the burden more heavily than physicians and care teams," said Ryan Fukushima, Chief Operating Officer at Tempus. "This evolution of Tempus One represents a meaningful shift from a world where clinicians spend countless hours searching for answers and documenting care, to one where AI rapidly connects the dots across fragmented systems to deliver actionable insights in real time."
To learn more about Tempus One, view a video here and visit the website here.
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the expected outcomes and benefits of Tempus One and its capabilities for customers. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "going to," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.
You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" in Tempus’ Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ("SEC") on February 24, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
